The U.S. Food and Drug Administration approved Zepatier with or without ribavirin for the treatment of chronic hepatitis C virus (HCV) for genotypes 1 and 4 in adults. An estimated 3.5 million people in the United States are infected with chronic HCV and genotype 1 is the most common genotype. The safety and efficacy of Zepatier […]

Go to Original Post